ImageneBio (IMA) Debt to Equity (2023 - 2024)
ImageneBio's (IMA) quarterly Debt to Equity came in at -$0.05 in Q4 2024, down 607.77% year-on-year from $0.01 in Q1 2024, and down 607.77% quarter-over-quarter from -$0.01 in Q4 2023.
ImageneBio (IMA) Debt to Equity (2023 - 2024) Analysis & Trends
ImageneBio has disclosed Debt to Equity across 2 years of filings, most recently posting -$0.05 for Q4 2024.
- Debt to Equity for Q4 2024 came in at -$0.05, down 607.77% year-over-year; the trailing twelve-month figure through Dec 2024 was -$0.05 (down 607.77% YoY), and the FY2024 annual result was -$0.05, down 607.77% from the prior year.
- Debt to Equity came in at -$0.05 for Q4 2024 at ImageneBio, down from -$0.01 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.01 in Q3 2023 to a low of -$0.05 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | ImageneBio | 3.18 Mn | 3.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -0.05 |
| Dec 31, 2023 | -0.01 |
| Sep 30, 2023 | 0.01 |